Evidence map›Paper›PMID 32038769›Full record

ArticleACS medicinal chemistry letters2019

Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol

Glen Ernst, Daniel Akuma, Vinh Au, Ingrid P Buchler, Spencer Byers, Gregory V Carr, Sabine Defays, Pablo de León, Thierry Demaude, Michael DePasquale and 15 more

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Catechol-Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Review
  4. 1-Hydroxy-2(1Molecules (Basel, Switzerland) · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 2 countries.

Glen ErnstLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Daniel AkumaLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Vinh AuLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Ingrid P BuchlerLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Spencer ByersLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Gregory V CarrLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Sabine DefaysUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Pablo de LeónLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Thierry DemaudeUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Michael DePasqualeLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Véronique DurieuUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Yifang HuangLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Emilie JigorelUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Martha KimosLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Anna KolobovaLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Florian MontelUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Florence MoureauUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Michael PoslusneyLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Dominique SwinnenUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Marie-Christine VandergetenUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Nathalie Van HoutvinUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
Huijun WeiLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Noelle WhiteLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Martyn WoodUCB Biopharma, SPRL, B-1420 Braine-L'Alleud, Belgium.
James C BarrowLieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States.
Lieber Institute for Brain Development · USUCB Pharma (Belgium) · BEJohns Hopkins University · US

Funding

Drug discovery of COMT inhibitors to treat cognitive deficits in schizophreniaR01MH107126 · NIMH · LIEBER INSTITUTE, INC. · PI BARROW, JAMES · 2015 to 2019
$4.1M
NIMH NIH HHS R01 MH107126
6 · The paper itself

Abstract

A series of bicyclic pyridones were identified as potent inhibitors of catechol

Identifiers

PMID32038769
PMCPMC7003998
OpenAlexW2981778137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.